Phase 1 Study of ACTR087, Autologous T Lymphocytes Expressing Antibody Coupled T-cell Receptors (CD16V-41BB-CD3ζ), in Combination With Rituximab, in Subjects With Relapsed or Refractory CD20-Positive B-Cell Lymphoma

Trial Profile

Phase 1 Study of ACTR087, Autologous T Lymphocytes Expressing Antibody Coupled T-cell Receptors (CD16V-41BB-CD3ζ), in Combination With Rituximab, in Subjects With Relapsed or Refractory CD20-Positive B-Cell Lymphoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Feb 2017

At a glance

  • Drugs ACTR 087 (Primary) ; Rituximab
  • Indications B cell lymphoma
  • Focus Adverse reactions
  • Sponsors Unum Therapeutics
  • Most Recent Events

    • 06 Dec 2016 Trial design presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 09 Aug 2016 Status changed from not yet recruiting to recruiting.
    • 20 Jun 2016 According to an Unum Therapeutics media release, the investigational new drug (IND) application for ACTR087 has been accepted by FDA and the company anticipates that study enrollment will begin in the second half of 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top